OTIC News and Press, Otonomy Inc. From 05/14/21

Otonomy (OTIC) announces preclinical proof-of-concept results for OTO-825 at the ASGCT Annual Meeting. OTO-825 is an AAV-mediated gene therapy developed in collaboration with Applied Genetic Technologies Corporation (AGTC).The results demonstrate that a single administration of OTO-825 rescue...

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical proof-of-concept results for OTO-825 presented at the American Society of Gene &...

Otonomy, Inc. (OTIC) Q1 2021 Earnings Conference Call May 11, 2021, 16:30 ET Company Participants Robert Uhl - MD David Weber - President, CEO & Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Stacy Ku - Cowen and Company Charles Duncan - Cantor F...

Otonomy (OTIC): Q1 GAAP EPS of -$0.23 in-line.Revenue of $0.09M (-43.8% Y/Y) beats by $0.06M.Press Release For further details see: Otonomy EPS in-line, beats on revenue

OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 OTO-825 IND-enabling activities underway with prec...

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4...

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the upcoming presentation of preclinical proof-of-concept data for OTO-825 at the American So...

Gainers: [[OTIC]] +10.4%. [[ASRV]] +5.2%. [[ANGI]] +3.3%. [[HLIT]] +2.7%. [[GDS]] +2.7%.Losers: [[VNET]] -7.7%. [[IMMP]] -5.1%. [[MIND]] -4.6%. [[AMRN]] -4.1%. [[TLSA]] -3.2%. For further details see: OTIC, HLIT, VNET and TLSA among after-hours movers

Gainers: Auris Medical (EARS) +18%, Prometheus Biosciences (RXDX) +15%, Crinetics Pharmaceuticals (CRNX) +13%, Genprex (GNPX) +12%, Fortress Biotech (FBIO) +12%.Losers: Endo International (ENDP) -10%, Odonate Therapeutics (ODT) -9%, Otonomy (OTIC) ...

Otonomy (OTIC) has priced its public offering of ~6.3M common shares at $2.25/share and, pre-funded warrants to purchase up to ~7.1M shares at $2.249/pre-funded warrant.Expected gross are ~$30.1M.Underwriters' over-allotment is an additional 2.01M shares. Cowen and Piper Sandler are acting as...